PTC Therapeutics | PTCT - Gross Profit On Sales


PTC Therapeutics reported $148.38M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Gilead Sciences USD 6.31B 106M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
TG Therapeutics USD 154.43M 20.81M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xencor USD 21M 22.61M Sep/2025